



AN 2002:868928 CAPLUS Full-text
 DN 137:352900
 TI Selective anthranilamide pyridine amides as inhibitors of VEGFR-2 and

VEGFR-3
 IN Ernst, Alexander; Huth, Andreas; Krueger, Martin; Thierauch, Karl-Heinz;
 Menrad, Andreas; Haberey, Martin
 PA Schering Aktiengesellschaft, Germany
 SO PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002090352	A2	20021114	WO 2002-EP4924	20020503
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10123574	A1	20021128	DE 2001-10123574	20010508
	DE 10125294	A1	20021121	DE 2001-10125294	20010515
PRAI	DE 2001-10123574	A	20010508		
	DE 2001-10125294	A	20010515		
	DE 2001-10164590	A	20011221		
OS	MARPAT 137:352900				
GI					



AB Title compds. I [G, L, M, Q = N, (un)substituted CH, ≤1 of them being N; R = (un)substituted N heterocycle; R¹ = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl] were prepared I are inhibitors of VEGFR-2 and VEGFR-3 and are used as medicaments for treating diseases that

BEST AVAILABLE COPY

are caused by persistent angiogenesis, such as psoriasis, Kaposi's sarcoma, restenosis, such as e.g. stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia, arthritis, such as rheumatoid arthritis, hemangioma, angiofibromatosis, in eye diseases such as diabetic retinopathy, neovascular glaucoma, in kidney diseases such as glomerulonephritis, diabetic nephropathy, malign. nephrosclerosis, thrombotic micro-angiopathic syndrome, transplant rejection and glomerulopathy, in fibrotic diseases such as hepatic cirrhosis, mesangial-cell proliferative diseases, arteriosclerosis, damage to the nerve tissue and inhibition of the re-occlusion of vessels after balloon catheter treatment, in vessel prosthetics or after the use of mech. devices for keeping vessels open, e.g. stents, as immunosuppressants, to support wound healing without scars and in cases of age spots and contact dermatitis. I can also be used as inhibitors of VEGFR-3 in lymphangiogenesis for hyperplastic and dysplastic changes in the lymphatic system. Thus, 2-amino-N-isoquinolin-3-ylbenzamide was treated with 2-bromo-5-pyridinecarboxaldehyde, followed by carboxylation and amidation to give the amide II. II had IC50 for inhibition of VEGFR-2 of 40 nM and for inhibition of cytochrome 450 isoenzyme 2C9 of 2.9 µM.

IT 474798-53-3P 474798-54-4P 474798-55-5P
 474798-56-6P 474798-57-7P 474798-58-8P
 474798-59-9P 474798-60-2P 474798-61-3P
 474798-62-4P 474798-63-5P 474798-64-6P
 474798-65-7P 474798-66-8P 474798-67-9P
 474798-68-0P 474798-75-9P 474798-76-0P
 474798-77-1P 474798-78-2P 474798-79-3P
 474798-80-6P 474798-81-7P 474798-82-8P
 474798-83-9P 474798-84-0P 474798-85-1P
 474798-86-2P 474798-87-3P 474798-88-4P
 474798-89-5P 474798-90-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)
 (preparation of


isoquinolinylcarbamoylphenylaminomethylpyridinecarboxamides
 as VEGFR-2 and VEGFR-3 inhibitors)

RN 474798-53-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-[[[2-[[[3-

(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-

(9CI) (CA
 INDEX NAME)




RN 474798-54-4 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-hydroxypropyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-

(9CI) (CA

INDEX NAME)




RN 474798-55-5 CAPLUS

CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-

(9CI) (CA

INDEX NAME)




RN 474798-56-6 CAPLUS

CN 2-Pyridinecarboxamide, N-(5-hydroxypentyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-

(9CI) (CA

INDEX NAME)




RN 474798-57-7 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-hydroxybutyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-


(9CI) (CA

INDEX NAME)




RN 474798-58-8 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-4-[[[2-
 [[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 474798-59-9 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-4-[[[2-
 [[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 474798-60-2 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-4-[[[2-[[[3-
 (trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 474798-61-3 CAPLUS


CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474798-62-4 CAPLUS

CN 2-Pyridinecarboxamide, N-(2-hydroxy-2-methylpropyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA INDEX NAME)



RN 474798-63-5 CAPLUS


CN 2-Pyridinecarboxamide, N-(3-hydroxy-3-methylbutyl)-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA INDEX NAME)



RN 474798-64-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-


(9CI) (CA INDEX NAME)



RN 474798-65-7 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-


(9CI) (CA INDEX NAME)



RN 474798-66-8 CAPLUS

CN 2-Pyridinecarboxamide, N-4-pyridinyl-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-

(9CI) (CA INDEX NAME)




RN 474798-67-9 CAPLUS


CN 2-Pyridinecarboxamide, N-3-pyridinyl-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-

(9CI) (CA


INDEX NAME)



RN 474798-68-0 CAPLUS
 CN 2-Pyridinecarboxamide, N-2-pyridinyl-4-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)




RN 474798-75-9 CAPLUS
 CN 2-Pyridinecarboxamide, N-(3-hydroxypropyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)




RN 474798-76-0 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 474798-77-1 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(1S)-2-hydroxy-1-methylethyl]-5-[[[2-
 [[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 474798-78-2 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(1R)-2-hydroxy-1-methylethyl]-5-[[[2-
 [[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 474798-79-3 CAPLUS

CN 2-Pyridinecarboxamide, N-4-pyridinyl-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA INDEX NAME)




RN 474798-80-6 CAPLUS

CN 2-Pyridinecarboxamide, N-3-pyridinyl-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA INDEX NAME)




RN 474798-81-7 CAPLUS


CN 2-Pyridinecarboxamide, N-(5-hydroxypentyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA INDEX NAME)




RN 474798-82-8 CAPLUS
 CN 2-Pyridinecarboxamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-
 [[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)



RN 474798-83-9 CAPLUS
 CN 2-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)




RN 474798-84-0 CAPLUS
 CN 2-Pyridinecarboxamide, N-(2-methoxyethyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
 (9CI) (CA
 INDEX NAME)




RN 474798-85-1 CAPLUS


CN 2-Pyridinecarboxamide, N-2-pyridinyl-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA
INDEX NAME)




RN 474798-86-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA
INDEX NAME)



RN 474798-87-3 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-hydroxy-3-methylbutyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA
INDEX NAME)




RN 474798-88-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(2-hydroxy-2-methylpropyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA
INDEX NAME)



RN 474798-89-5 CAPLUS


CN 2-Pyridinecarboxamide, N-[(2R)-2-hydroxypropyl]-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 474798-90-8 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-hydroxybutyl)-5-[[[2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]methyl]-
(9CI) (CA
INDEX NAME)



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox